Arkolith/Insider Trading/ESPR/Form 4

Halladay Benjamin

Chief Financial OfficerEsperion Therapeutics, Inc. (ESPR) · full profile →Form 4 · filed Jan 21, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$20
Net Open-Market Flow
-$20
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 17, 2025Sell(S)9$2.27$20241K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-25-002037) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML